Dr. Alejandro Rojas Fernández is an accomplished biochemist and molecular biologist recognized for his pioneering work in the development of neutralizing antibodies against emerging infectious diseases. During the COVID-19 pandemic, he was among the first scientists worldwide to engineer neutralizing nanoantibodies against the SARS-CoV-2 coronavirus, gaining international attention for his innovative approach and rapid contributions to global health efforts. His research not only advanced therapeutic strategies but also positioned antibody engineering as a frontline tool against future pandemics.

Dr. Rojas has dedicated much of his career to understanding and countering highly pathogenic viruses, including Hantavirus, a rodent-borne pathogen responsible for severe respiratory syndromes, and Nipah virus, a zoonotic virus with high fatality rates and pandemic potential. His work has focused on exploiting the unique properties of camelid-derived nanobodies, which combine small size, high stability, and strong binding affinity—making them powerful candidates for antiviral therapeutics and diagnostics.

With a background in both academia and translational research, Dr. Rojas has successfully bridged the gap between discovery and application, advancing the development of next-generation biologics. He has collaborated with international institutions, governments, and industry to accelerate responses to viral outbreaks, always emphasizing innovation, accessibility, and preparedness.

Today, Dr. Rojas continues to expand his research on antibody-based therapies, leading efforts to confront current and future viral threats with cutting-edge biotechnology.